Table 3. Comparison of dose–volume indices between with and without consideration of intra-fraction prostate motion.

		Without motion (Mean ± SD)	With motion (Mean ± SD)	Difference between mean values	Relative error (%)	p-value
CTV	D2% (Gy)	42.78 ± 1.87	42.72 ± 1.82	−0.06	−0.14	0.12*
	D50% (Gy)	39.15 ± 1.10	39.07 ± 1.06	−0.08	−0.20	0.011
	D98% (Gy)	35.24 ± 0.58	35.16 ± 0.61	−0.08	−0.22	0.051
	HI	0.19 ± 0.05	0.19 ± 0.05	0.00	0.42	0.50*
PTV	D2% (Gy)	42.59 ± 1.85	42.53 ± 1.79	−0.07	−0.15	0.083*
	D50% (Gy)	38.64 ± 0.99	38.55 ± 0.96	−0.09	−0.22	0.007
	D98% (Gy)	33.73 ± 0.65	33.63 ± 0.72	−0.10	−0.29	0.005*
	HI	0.23 ± 0.05	0.23 ± 0.06	0.00	0.49	0.13*
Rectum	D5cc (Gy)	26.95 ± 2.45	26.86 ± 2.35	−0.10	−0.32	0.25*
	V50% (%)	30.47 ± 3.69	30.45 ± 3.74	−0.02	−0.08	0.71
Bladder	D10cc (Gy)	27.32 ± 2.68	27.26 ± 2.67	−0.06	−0.20	0.25*
	V100% (cc)	1.88 ± 1.15	1.81 ± 1.12	−0.07	−6.00	0.11
Urethra	D10% (Gy)	37.29 ± 1.75	37.24 ± 1.74	−0.05	−0.14	0.31
	D30% (Gy)	28.86 ± 7.49	28.95 ± 7.14	0.09	1.18	1.0*

*p-value from non-parametric test.

CTV, clinical target volume; PTV, planning target volume; SD, standard deviation; HI, homogeneity index.